


Vaniprevir

Chemical Properties

CAS No. :	923590-37-8
Formula:	C ₃₈ H ₅₅ N ₅ O ₉ S
Molecular Weight:	757.94
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Vaniprevir is a non-covalent competitive HCV NS3/4A protease inhibitor, an antiviral drug that acts directly on the hepatitis C virus. Vaniprevir blocks the viral replication process by inhibiting the activity of HCV NS3/4A protease.
Targets(IC50)	HCV Protease
In vitro	Sensitivity of 39 HCV-treated clinical isolates to VX-950 (telaprevir), SCH-503034 (boceprevir), ITMN-191, Vaniprevir, and TMC-435350 were evaluated using a replicon-based NS3 protease phenotype assay. Some natural changes in susceptibility between these isolates were observed when testing all five HCV PIs (VX-950, SCH-503034, ITMN-191, Vaniprevir, and TMC-435350). The order of variations is from minimum to maximum Vaniprevir < VX-950 < ITMN-191 < SCH-503034 < TMC-435350. [6]

Solubility Information

Solubility	DMSO: 8 mg/mL (10.55 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3194 mL	6.5968 mL	13.1937 mL
5 mM	0.2639 mL	1.3194 mL	2.6387 mL
10 mM	0.1319 mL	0.6597 mL	1.3194 mL
50 mM	0.0264 mL	0.1319 mL	0.2639 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Liverton, Nigel J.; Carroll, Steven S.; Di Muzio, Jillian;.MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. *Antimicrobial Agents and Chemotherapy* (2009), Volume Date 2010, 54(1), 305-311.
- Kong J, Chen CY, Balsells-Padros J, Cao Y, Dunn RF, Dolman SJ, Janey J, Li H, Zacuto MJ.Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.*J Org Chem.* 2012 Apr 20;77(8): 3820-8. Epub 2012 Apr 10.
- Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group.Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with c
- Song ZJ, Tellers DM, Journet M, Kueth JT, Lieberman D, Humphrey G, Zhang F, Peng Z, Waters MS, Zewge D, Nolting A, Zhao D, Reamer RA, Dormer PG, Belyk KM, Davies IW, Devine PN, Tschaen DM.Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-m
- McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ.Discover
- Bae A, et al. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. *Antimicrob Agents Chemother.* 2010 Dec;54(12):5288-97. 6.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481